ExodusPoint Capital Management’s Relay Therapeutics RLAY Stock Holding History

ExodusPoint Capital Management’s Portfolio RLAY Stock Details RLAY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.45M	Buy	+184,178	New	+$2.67M	0.02%	616
2026 Q1	–	Sell	-1,141,880	Closed	-$9.66M	–	2016
2025 Q4	$9.66M	Buy	+1,141,880	New	+$8.15M	0.08%	266
2025 Q3	–	Sell	-170,196	Closed	-$589K	–	1939
2025 Q2	$589K	Buy	+170,196	New	+$506K	0.01%	1111
2024 Q1	–	Sell	-82,761	Closed	-$911K	–	1894
2023 Q4	$911K	Buy	+82,761	New	+$698K	0.01%	852
2023 Q1	–	Sell	-104,736	Closed	-$1.56M	–	2073
2022 Q4	$1.56M	Buy	+104,736	New	+$2M	0.02%	753

Other funds holding RLAY

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

ExodusPoint Capital Management's RLAY Position: Q2 2026 in Review

ExodusPoint Capital Management opened a new position in Relay Therapeutics (RLAY) in Q2 2026: 184,178 shares worth $3.45M. The stake represents 0.02% of the portfolio and ranks #616 among its holdings. This is a return to the name: ExodusPoint Capital Management previously reported a position in RLAY as recently as Q4 2025.

ExodusPoint Capital Management first reported a position in RLAY in Q4 2022 and has held it in 5 quarters since. The position peaked at $9.66M in Q4 2025. 259 funds tracked by Wall St. Rank hold RLAY as of Q2 2026.

ExodusPoint Capital Management held 184,178 shares of Relay Therapeutics worth $3.45M as of Q2 2026.
Relay Therapeutics was a new ExodusPoint Capital Management position in Q2 2026.
Relay Therapeutics made up 0.02% of ExodusPoint Capital Management's portfolio in Q2 2026, its #616 holding.
ExodusPoint Capital Management first reported a position in Relay Therapeutics in Q4 2022 and has held it in 5 quarters since.
ExodusPoint Capital Management's Relay Therapeutics position peaked at $9.66M in Q4 2025.
259 funds tracked by Wall St. Rank held Relay Therapeutics as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.